Actively Recruiting
Beta-Cell - Liver Interactions in Situations of Modified Beta-Cell Function From Mice to Children
Led by Philippe Klee, MD-PhD · Updated on 2026-05-18
50
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
P
Philippe Klee, MD-PhD
Lead Sponsor
U
University of Geneva, Switzerland
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying blood levels of 1,5-anhydroglucitol (1,5-AG) in obese children aged 12 to 16, with or without type 2 diabetes, to see how these levels relate to beta-cell mass and glucose metabolism. This study aims to test 1,5-AG as a new marker for beta-cell function in children with obesity. The research builds on findings from mouse models and previous studies linking 1,5-AG to diabetes progression and blood sugar control. The study will measure 1,5-AG blood levels in 50 children during planned oral glucose tolerance tests, first at enrollment and again two years later. These measurements will be compared with markers related to beta-cell function, beta-cell mass, and liver function indicators. The study is observational and involves no treatment interventions. Participants will be evaluated twice over two years, with blood tests and oral glucose tolerance tests to assess beta-cell function and metabolic control. Researchers will correlate 1,5-AG levels with these parameters as the primary outcome. Secondary outcomes include examining 1,5-AG associations with liver function. The study will monitor participants’ health and metabolic data to better understand beta-cell and liver interactions in obese children.
CONDITIONS
Brief Title
Beta-Cell - Liver Interactions in Situations of Modified Beta-Cell Function
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Children aged 12 to 16 years
- Obesity defined as body-mass index above the 97th percentile
- Ability to give informed consent as documented by signature
You will not qualify if you...
- Patients with diabetes mellitus and positive autoantibodies against islets, insulin, islet antigen 2, glutamic acid decarboxylase or Zinc transporter 8
- Patients with known liver disease other than non-alcoholic fatty liver disease (NAFLD)
- Patients treated with an oral antidiabetic drug, glucagon-like peptide-1 analogues or insulin at the time of or less than 2 weeks prior to inclusion
- Patients treated with a drug known to affect liver function
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Day 1
Participants undergo measurements of blood levels of 1,5-anhydroglucitol and oral glucose tolerance tests to evaluate beta-cell function and liver indicators.
1 visit (in-person)
Duration - 2 years
Participants are followed over 2 years with repeated biomarker measurements and oral glucose tolerance tests to monitor beta-cell function and liver health.
1 visit at 2 years (in-person)
Trial Site Locations
Total: 1 location
1
University Hospital of Geneva
Geneva, Canton of Geneva, Switzerland, 1211
Actively Recruiting
Research Team
P
Philippe Klee
P
Pierre Maechler
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here